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Abstract
Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other 
comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in 
three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important 
challenges in medicine. Is it, however, in fact possible to prevent epilepsy?
Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-
-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated 
cognitive impairment in children. 
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Epilepsy affects approximately 50 million patients world-
wide, with an incidence in paediatric patients that varies from 
3.4 to 5.8 per 1,000 [1]. Effective epilepsy treatment and swift 
seizure cessation are especially important in children in whom 
uncontrolled seizures deteriorate the psychomotor functions, 
which leads to cognitive impairment and reduced quality of 
life in adulthood [2, 3]. Regardless of the immense progress in 
epilepsy treatment that has been made in recent years, drug-
-resistant epilepsy still afflicts roughly 30% of patients [4]. 
Therefore to the goal should be to try to prevent epilepsy. The 
question is whether the prevention of epilepsy is truly possible? 
It has been documented that the process of epilepsy deve-
lopment (epileptogenesis) begins with an insulting/triggering 
factor (i.e. genetic mutation, injury, metabolic disease). This 
is followed by a latent period of changes in protein expres-
sion and ion channel functioning, and finally manifests with 
clinical seizures [5]. However, the epileptogenic process does 
not end with the occurrence of clinical epilepsy, but persists 
beyond the initial seizures, leading to the development of 
drug-resistant epilepsy and epilepsy-related comorbidities [5]. 
Thus, a better understanding of epileptogenesis may lead to 
the development of new, antiepileptogenic (AEG) therapies. 
There is an important difference between the terms antie-
pileptic (AED) and antiepileptogenic (AEG) drugs. AEDs 
(e.g. phenytoin, carbamazepine) are implemented after seizure 
onset and reduce seizure frequency and severity but do not 
influence epileptogenesis [5, 6]. On the other hand, AEGs may 
be introduced before or after epilepsy onset, and they change 
the natural course of epilepsy by counteracting epileptogenesis 
by prevention, seizure modification, reduction or prevention 
of the progression of epilepsy, or curing. Therefore, currently, 
the terms antiseizure (ASD) or anticonvulsant, rather than 
antiepileptic drug (AED) are beginning to be used in order to 
better distinguish the antiepileptogenic from the antiseizure 
effects of action [6].  
In the light of recent studies on epileptogenesis, a first 
step to prevent epilepsy is to identify patients with a high 
risk of epilepsy development before the occurrence of clinical 
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seizures. It is well known that patients after traumatic brain 
injury or stroke have an increased risk of epilepsy [7, 8]. Ho-
wever, objective studies on epileptogenesis and the possibility 
of its prevention are difficult in these groups of patients due 
to their considerable heterogeneity in terms of their aetiology, 
epilepsy risk, and the variety of environmental and individual 
factors that influence epileptogenesis [5, 7, 8]. 
On the other hand, some paediatric genetic diseases are 
highly associated with early-onset epilepsy, leading to more 
homogenous groups, and patients may be diagnosed before the 
development of clinical seizures, which enables a preventive 
intervention. Therefore, such children may be a perfect group 
for possible preventive antiepileptogenic treatment and studies 
of epileptogenesis. 
Sturge-Weber syndrome (SWS) is a vascular neurocuta-
neous disorder with an incidence of 1 in 20,000–50,000 live 
births and it is characterised by a very high overall risk of 
epilepsy, that reaches 80-90% in the first two years of life 
[9, 10]. Due to a characteristic facial naevus, SWS can be 
diagnosed early, before epilepsy [11]. The study of Ville et al. 
demonstrated that preventive treatment with phenobarbital in 
SWS patients significantly decreased the incidence of epilepsy 
and delayed development compared to the control SWS group 
treated after first seizures [12]. The presence of developmental 
venous anomalies and decreased brain tissue perfusion leading 
to anoxic brain injury are the major contributory factors to epi-
leptogenesis in SWS [13–15]. Early identification of potential 
predicting factors, combined with prophylactic antiepilepto-
genic therapy, may significantly improve the clinical outcome 
and life quality of patients. 
Another paediatric model for possible antiepileptogenic 
intervention is tuberous sclerosis complex (TSC). This is 
a genetic neurocutaneous disorder with a high risk of early 
onset epilepsy (70–90%) associated with cognitive impairment 
(50–60% of TSC patients) and autistic behaviour [16]. TSC 
is more frequent than SWS, affecting 1 in 6,000 people and 
can be diagnosed very early, before clinical seizures, and even 
prenatally [16, 17]. The first seizures in TSC usually occur 
within first two years of life, mostly at the age of 4–6 months, 
and it has been proved that epileptiform discharges in elec-
troencephalography (EEG) precede clinical seizures in TSC 
infants, being a good predictive factor for preventive treatment 
[18–20]. Based on the evolution pattern from epileptic EEG 
record to clinical seizures, we performed in our previous stu-
dy regular EEG studies in infants with TSC and introduced 
preventive treatment with vigabatrin when ictal discharges 
occurred in EEG, but before clinical seizures [21]. At the age 
of 24 months, significantly more children in the preventive 
group were seizure-free compared to the standard group tre-
ated after clinical seizures (35% vs 93%, p = 0.004). Moreover, 
fewer children in the preventive cohort had drug-resistant 
epilepsy (7% vs 42%, p = 0.021). Also, of great importance for 
parents and children, the cognitive functioning of children 
treated before clinical seizures was significantly better (mean 
IQ: 92.3 vs 68.7, p < 0.05) and intellectual disability was also 
less frequent (14.3% vs 48.4%, p = 0.031) [21]. 
Besides the abovementioned treatment implications, new 
and interesting therapy approaches are emerging. Mutations 
in TSC1 or TSC2, encoding two tumour suppressor proteins 
of the mammalian target of rapamycin (mTOR) pathway, 
are known to cause TSC [22]. The mTOR signalling pathway 
is recognised as regulating a number of cellular processes 
required in the growth, metabolism, structure and intera-
ctions of neuronal cells [23]. Inactivation of one of the TSC 
genes results in overactivation of the mTOR pathway, leading 
to the development of benign tumours or hamartomas in 
multiple organs. In the majority of patients, the brain is one 
of the most affected organs, which results in epilepsy, deve-
lopmental delay, and neurobehavioural or neuropsychiatric 
disorders [24]. The establishment of a connection between 
TSC1/TSC2 mutations and mTOR led to the clinical use of 
drugs known as mTOR inhibitors: sirolimus and everolimus. 
These are becoming an increasingly interesting tool in the 
management of TSC-associated symptoms and epileptogenesis 
[23, 25]. It has been demonstrated that mTOR inhibitors can 
be used in the treatment of many features of TSC, including 
subependymal giant cell astrocytomas (SEGA), renal angio-
myolipomas (AML), lymphangioleiomyomatosis (LAM), and 
skin lesions [26–29]. Moreover, EXIST-3, a recent prospective, 
randomised, multicentre, placebo-controlled study, established 
that everolimus can be used as adjunctive therapy for the 
treatment of refractory seizures associated with TSC [30]. 
Everolimus reduces seizure frequency in a dose-dependent 
manner with a tolerable safety profile in TSC patients with 
refractory epilepsy [30]. The odds for response in patients 
treated with everolimus were 2.2–3.9 times higher than with 
a placebo [30]. Furthermore, a positive effect of everolimus 
has been observed in a variety of seizure types [30]. 
In conclusion, we feel that the mTOR pathway represents 
a great opportunity for future novel antiepileptogenic drugs. 
Moreover, another benefit of the use of mTOR inhibitors in 
TSC is the possibility of simultaneously improving not only 
one manifestation, e.g. SEGA or seizures, but also other TSC 
symptoms. The currently available findings regarding mTOR 
inhibitors, both clinical and pre-clinical, are intriguing and 
highly supportive of future experiments.
Currently, TSC is considered to be one of the best models 
for prospective studies of epileptogenesis in humans due to 
a homogenous group of patients, the possibility of a diagnosis 
before seizures, and the possibility of early (before clinical 
seizures) and easy detection of epileptogenesis based on ictal 
discharges on EEG. 
Hence, at present there are two large, multicentre studies 
on epilepsy prevention in TSC in Europe and the US ongoing: 
EPISTOP (ClinicalTrials.gov Identifier: NCT02098759) (www.
epistop.eu) and PREVENT (ClinicalTrials.gov Identifier: 
192
Neurologia i Neurochirurgia Polska 2019, vol. 53, no. 3
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
NCT02849457). The EPISTOP project is focused not only 
on the prevention of epilepsy but also on the identification 
of the clinical and molecular biomarkers of epileptogenesis 
in humans. The project ended in April 2019 and the results 
of EPISTOP may shed new light on the management and 
prevention of epilepsy in humans. 
Undoubtedly, the prevention of epilepsy is a serious 
challenge. However, prevention is possible, and it has been 
proved that preventive treatment may be particularly effective 
and important in epileptic encephalopathies such as TSC and 
SWS, reducing not only seizures but also their comorbidities 
[31]. Future studies using predictive biomarkers will demon-
strate the extent to which this may be useful in other types of 
seizures, and in adult patients.  
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